好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurocognitive Adverse Event Profile of USL255 (Qudexy® XR; Topiramate Extended-Release Capsules): Phase 3 PREVAIL and PREVAIL OLE Studies
Epilepsy/Clinical Neurophysiology (EEG)
(-)
222
Authors/Disclosures
Ilan Blatt
PRESENTER
No disclosure on file
Steve Chung, MD, FAAN (Banner University Medical Center) The institution of Dr. Chung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ucb pharma. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SK Life sciences. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for ucb. Dr. Chung has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life sciences. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for sunovion.
No disclosure on file
Huy Nguyen No disclosure on file
No disclosure on file
Mary J. Holmay, RN, BSN (Greenwich Biosciences (GW Pharmaceuticals)) No disclosure on file
Mark Halvorsen, PharmD (Upsher-Smith Laboratories, LLC) Dr. Halvorsen has received personal compensation for serving as an employee of Upsher-Smith Laboratories, LLC. Dr. Halvorsen has stock in Pfizer. Dr. Halvorsen has stock in Amgen. Dr. Halvorsen has stock in Stryker.
Robert E. Hogan, MD (Washington Univ in St Louis/Neuro Dept) Dr. Hogan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Hogan has received research support from Biogen Inc. The institution of Dr. Hogan has received research support from Engage Therapeutics. The institution of Dr. Hogan has received research support from Otsuka Pharmaceuticals. The institution of Dr. Hogan has received research support from Cerevel Therapeutics.